PureTech’s Karuna Gets Another $68m For Re-engineered Lilly CNS Candidate

Karuna Therapeutics plans to expand its development program for lead candidate KarXT beyond its current Phase II trial in schizophrenia. The series B financing follows a $42m series A in 2018.

Phoenix
Can xanomeline rise from the ashes? • Source: Shutterstock

Karuna Therapeutics Inc. has raised $68m in a series B round led by ARCH Venture Partners. The firm, an affiliate of PureTech Health PLC, was set up to revive development of the muscarinic acetylcholine receptor agonist xanomeline, formerly under development by Eli Lilly & Co. but discontinued because of its side effects.

Karuna’s KarXT is a co-formulation of xanomeline with the peripherally acting muscarinic antagonist trospium chloride. The purpose of the combination...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.